FBXO42 Inhibition for Mutant Notch Signaling in Leukemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological strategies for targeting the Notch signaling pathway in Notch-activated cancers, particularly T-cell leukemia, are insufficient due to side effects and the activation mechanism of RBPJ, a critical transcription factor, remaining unclear, making it difficult to modulate Notch pathway function effectively.
Innovation Solution
Utilizing a FBXO42 specific inhibitor, such as a polypeptide antagonist, polynucleotide, or small molecule compound, to target and down-regulate FBXO42, which interacts with RBPJ, thereby modulating Notch signaling and reducing its activity in Notch signaling-dependent diseases like leukemia, lymphoma, and breast cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If γ-secretase inhibitors are used to target Notch pathway, then Notch signaling activity is reduced, but side effects occur and mutant Notch does not require γ-secretase cleavage to be activated
Solution Approach 1:
The patent extracts and targets a specific component (FBXO42) downstream of Notch activation that is essential for mutant Notch pathway function. By inhibiting FBXO42 specifically, the therapy achieves Notch pathway suppression without affecting γ-secretase function, thereby avoiding the side effects associated with γ-secretase inhibitors while remaining effective against mutant Notch-driven cancers.
Solution Approach 2:
The patent introduces FBXO42 as an intermediary target between Notch activation and the transcriptional response. Instead of directly blocking Notch receptors or γ-secretase, the invention mediates pathway inhibition through FBXO42, which acts as a crucial downstream effector. This intermediary approach allows selective suppression of mutant Notch signaling while preserving normal cellular functions dependent on γ-secretase.
2Reliability
If RBPJ is targeted to modulate Notch transcription, then Notch signaling is inhibited, but the dual role of RBPJ in regulating Notch signaling makes it difficult to target effectively
Solution Approach 1:
The patent extracts the essential function of RBPJ in mutant Notch signaling by targeting FBXO42, which is required for RBPJ-mediated transcriptional activation. Rather than directly targeting RBPJ and its multiple functions, the invention isolates and inhibits FBXO42 as a specific downstream component, simplifying the targeting strategy while achieving effective Notch pathway suppression in mutant contexts.
Solution Approach 2:
Instead of directly targeting RBPJ and attempting to overcome its dual regulatory role, the patent inverts the approach by targeting FBXO42, a downstream effector that is essential for RBPJ function in mutant Notch signaling. This inverted strategy bypasses the complexity of RBPJ's dual role by acting on a component that is specifically required for the pathological signaling pathway.
3Adaptability or versatility
If new molecular targets downstream of Notch activation are identified, then therapeutic strategies are improved, but the need to develop new strategies remains urgent due to insufficient clinical use of current approaches
Solution Approach 1:
The patent performs preliminary identification and characterization of FBXO42 as a therapeutic target before clinical application. By pre-validating FBXO42's essential role in mutant Notch signaling through mechanistic studies and demonstrating its druggability, the invention reduces the time required for later clinical development compared to de novo target identification. The preliminary work establishes a clear rationale and proof of concept that accelerates subsequent translational processes.
Data Source
AI summary
The present invention refers to a method for treating Notch signaling-dependent disease in the subject with a FBXO42 specific inhibitor. The Notch signaling-dependent disease is selected from leukemia. Also provided is a method for screening a drug treating Notch signaling-dependent disease using FBXO42 as a target.